Background: Targeted therapies, associated with standard chemotherapies, have improved breast cancer care. However, primary and acquired resistances are frequently observed and the development of new concepts is needed. Highthroughput approaches to identify new active and safe molecules with or without an ''a priori'' are currently developed. Also, repositioning already-approved drugs in cancer therapy is of growing interest. The thiomorpholine hydroxamate compound TMI-1 has been previously designed to inhibit metalloproteinase activity for the treatment of rheumatoid arthritis. We present here the repositioning of TMI-1 drug in breast cancer.
Introduction
Breast cancer is a heterogeneous disease whose evolution is difficult to predict. Breast cancers can be subdivided in three groups upon biological features and associated therapies: tumors expressing estrogen (ER) and/or progesterone (PR) receptors, tumors overexpressing ERBB2, and triple negative (TN) tumors that lack ER, PR and express no or normal ERBB2 levels [1] . This classification led to the advent of ''targeted therapy'' for hormone receptor-positive and for ERBB2-overexpressing breast cancers, respectively. No routinely used targeted therapy for TN breast cancers exists. Gene expression profiling has identified major molecular subtypes -luminal, basal and ERBB2 -that are grossly but not completely overlapping with these groups [1] . TN and ERBB2 tumors are the most aggressive breast cancers.
New therapeutics expected to target molecular pathways involved in tumor expansion and progression are in development. These targets comprise tyrosine kinase receptors, signaling pathways molecules, angiogenic factors and inhibitors of DNA repair [2] . Even though recent data have demonstrated a marked efficiency of these new targeted therapies, it remains challenging to identify eligible patients for a given therapy. Moreover, acquired resistance are frequently noted in advanced disease due to loss of target or activation of downstream or alternative signaling pathways [3] . Thus, combinations of conventional chemotherapy and radiotherapy are still the standard of care for breast cancer.
Anthracycline/taxane-based neoadjuvant chemotherapy is routinely used for the treatment of the different breast cancer subtypes. Not only these treatments have adverse effects in patients but do not prevent relapses, which are now attributed to resistance of cancer stem cells to the drugs [4] .
Ideally, optimal chemotherapeutic drugs in development should have a marked inhibitory effect towards the largest panel of cancer cells and cancer stem cells, and reduced or no toxicity towards normal cells both in vitro and in preclinical models. Highthroughput approaches to identify such active molecules with or without an ''a priori'' are currently developed in many laboratories [5] . Also, drug repositioning has been recently considered as a real alternative and attractive means to rapidly reach cancer clinical trials [6] .
Metalloproteinases play a role in multiple steps of tumor progression such as angiogenesis, local invasion, intravasation, extravasation and formation of distant metastases [7] . Metalloproteinases belong to three families, including two large ones, matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase family (ADAM). ADAM-17 metalloproteinase inhibitors have been described as promising agents in the treatment of breast and lung cancers. ADAM-17 is involved in the shedding of EGFR (Epidermal Growth Factor receptor) ligands and ERBB2 and its targeting leads to decreased ERBB signaling [8, 9] . An ADAM-17 inhibitor is currently undergoing early clinical trials (Friedman et al., cancer research, meeting abstract). When testing different ADAM metalloproteinase inhibitors we identified one compound, named TMI-1, with unexpected properties. TMI-1 is a dual inhibitor of MMP and ADAM metalloproteinases [10] . We found that, in contrast to other ADAM inhibitors of the same family, TMI-1 killed breast tumor cell lines and was efficient in pre-clinical models. TMI-1 effect was mediated by cell cycle inhibition and induction of caspase-dependent apoptosis. TMI-1 is a valuable and promising repositionable drug for the treatment of breast cancer and probably for other types of cancer. This molecule defines a new class of chemical compound for the treatment of cancer.
Materials and Methods

Animals
FVB/N-Tg(MMTVneu)202Mul transgenic mice were purchased from the Jackson Laboratory (Bar Harbor, Maine 04609 USA). FVB/N and C57BL/6 mice were purchased from the Centre d'Elevage Roger Janvier (Le Genest-St-Isle, France). All mice were kept in a specific pathogen-free mouse facility and handled according to the rules of ''Décret no. 87-848 du 19/10/ 1987, Paris.'' All experiments were performed in agreement with the French Guidelines for animal handling and protocols described in this study and were reviewed and approved by the local ethics committee. Project: Comité Ethique-Provence #14 (Coordinated by J. Nunes, M. Aurrand-Lions and P. Gibier).
Cell lines
Cells were cultivated according to laboratory recommendations. The human breast carcinoma cell line L226 cell line was isolated from mouse xenografted with tumor biopsy (Mezil et al., in preparation). The patient gave written informed consent for xenograft protocol and cell line derivation. Isolation of a murine mammary tumor epithelial cell line (TgNeu27)
Mammary gland tumor was removed from euthanized MMTVneu mouse. Tumor was dissociated in a trypsin-EDTA 0.25% buffer (Invitrogen) for 30 min at 37uC. Dissociated cells were filtered then centrifugated at 1200 rpm for 10 min. Cells were plated in dishes in DMEM-F12 (Invitrogen) supplemented with 10% FCS and incubated at 37uC in 5% CO2. Cells were subcultivated as they reached high confluency. Characterization was done on the basis of transgene expression/activation and tumorigenicity (data not shown).
Reagents
TMI-1, TMI-2, TMI-005 were from the Wyeth company. Marimastat, batimastat were purchased from TOCRIS bioscience. Tanomastat was purchased from Agouron Pharmaceuticals. TAPI-1 was purchased from Peptide International. Docetaxel, doxorubicin and carbonyl cyanide m-chlorophenylhydrazone (CCCP) were from Sigma-Aldrich. Dihydroethidium was from Molecular Probes. Lapatinib was from Sequoia Research Products, United Kingdom. Z-VAD-FMK, Z-IETD-FMK, annexin V and 7-AAD (7-Aminoactinomycin D) were purchased from BD pharmingen. Anti-ERBB2 (sc-284) and anti-phosphotyrosine 1248 specific ERBB2 (PN2a) antibodies were from Santa-Cruz BT and Abcam companies, respectively.
Synthesis of compound TMI-1-O-Me
In a 10 mL two necked round flask were placed at room temperature 10 mg of TMI-1 (2.51610 25 mol) in 6 mL of anhydrous Methanol. 35 mg (2.51610 24 mol) of K 2 CO 3 were introduced followed by the addition of 36 mg (2.51610 24 mol, 16 mL) of methyl iodide. Stirring was maintained at room temperature overnight. Water (20 mL) and ethyl acetate (20 mL) were added to allow phase separation and the aqueous phase was extracted twice. The bottom phase layer was dried over Na 2 SO 4 , filtered and concentrated in vacuo. After removal of the solvents, the crude residue was purified by chromatography on a silicagel column using CH 2 Cl 2 /Ethylacetate (1/1) eluent affording the expected product in 75% yield.
Compound 
Characterization of cancer stem cells (CSC) population based on aldehyde dehydrogenase (ALDH) activity
To characterize CSCs, the Aldefluor kit (StemCell Technologies) was used. Briefly, cells were incubated in Aldefluor assay buffer containing ALDH substrate (BAAA (BODIPYH -aminoacetaldehyde), 1 mmol/L per 1610 6 cells). Negative control was done in the presence of diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. Cells were then incubated for 40 min at 37uC. Cells were analyzed with the LSRII flow cytometer (BectonDickinson). PI (Propidium Iodide) exclusion was used to gate viable cells.
Characterization of cancer stem cells population based on tumorsphere formation
To obtain primary tumorspheres, cells were plated in ultralow attachment plates (Corning) at a density of 1000 cells/mL. Cells were grown in a serum-free mammary epithelial growth medium (MEBM, Lonza), supplemented with B27 (GIBCO), 20 ng/mL EGF, 2 mg/mL hydrocortisone, 2 mg/mL insulin actrapid and 50 mM b-mercaptoethanol (GIBCO). To obtain secondary tumorspheres, primary tumorspheres were collected by centrifugation and dissociated enzymatically (10 min at 37uC in 0.05% trypsin, Invitrogen) and mechanically, using a fire-polished Pasteur pipette. Cells were counted and seeded in ultralow attachment plates (Corning) at a density of 1000 cells/mL.
Cell growth/viability measurement
To analyze the effect of different drugs, cell growth was measured using the alamarBlue staining procedure as recommended by the manufacturer (Biosource). The test incorporates a fluorescent oxidation-reduction indicator. Fluorescence intensity is proportional to cellular metabolic reduction. Experiments were done by incubating 3000 cells/well in triplicate at Day 0 in 96 well plates. AlamarBlue was measured at Day 5 by incubating 1/ 10 volume of alamarBlue solution for 2 h at 37uC and read at 595 nm (FLUOstar Optima, BMG Labtech).
Cell cycle analysis
SUM149 cells (10 6 ) were incubated with TMI-1 for 48 h at indicated concentrations. Cells were treated according to the manufacturer's recommendations (BD Pharmingen, BrdU (Bromodeoxyuridin) Flow Kit). FITC conjugated BrdU antibody was incubated for 20 min at room temperature. Cells were washed and resuspended in a buffer containing 7-AAD. Cell cycle distribution was analyzed with a FACScalibur flow-cytometer (BectonDickinson). Analysis was done using the BD CellQuest flow cytometry analysis software.
Analysis of caspase activity
Caspase activities were determined using commercially available kits. For the measurement of caspase-3/7 activity, 10 5 cells were incubated in triplicate in 96 plates. TMI-1 at indicated concentrations was incubated for 24 h at 37uC. Activity was determined using luminescence Caspase-Glo Assays (Promega) according to the manufacturer's instruction. For the measurement of caspase-8 and caspase-9, 10 6 cells/mL were incubated with TMI-1 at indicated concentrations for 48 h at 37uC. One mL of Red-IETD-FMK (caspase-8 test) or Red-LEHD-FMK (caspase-9 test) was added for 1 h at 37uC according to the manufacturer's recommendations (Biovision). Cells were washed then analyzed with the LSRII flow cytometer.
Measurement of ROS production
Intracellular generation of ROS was measured using dihydroethidium. Cells (10 6 ) were treated with TMI-1 or CCCP at indicated concentrations for 48 h. Cells were trypsinized then stained with 5 mM dihydroethidium for 30 min at 37uC. Ethidium fluorescence intensity resulting from dihydroethidium oxidation was measured using the LSRII flow cytometer.
Western blot analysis
Cells and tumors were lyzed in ice-cold lysis buffer containing 50 mM Hepes, pH 7.5, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 0.2 mM sodium ortho-vanadate and 10% glycerol. ''Complete'' Protease Inhibitor Cocktail was added to cold lysis buffer as recommended by the manufacturer (Roche Diagnostics).
Cell lysates (25 mg) were separated using NuPAGE 4-12% Novex Bis-Tris gels according to manufacturer's recommendations (Invitrogen) and transferred onto Hybond TM -C membrane (GE Healthcare Life Sciences). Membranes were blocked in PBS supplemented with 5% BSA for 1 h and then incubated with indicated antibodies. After washing, membranes were incubated with the secondary antibody conjugated with horseradish peroxidase (Pierce). The signal was detected using the ECL system (GE Healthcare Life Sciences).
Transfection
Plasmids were transfected into SUM149 cells via the Nucleofector technology, as recommended by the manufacturer (Amaxa GmbH). Briefly, 5.10 6 cells were resuspended in 100 mL Cell Line Nucleofector Solution V and nucleofected with 2 mg of each vector using program V-001 (Amaxa GmbH). Following nucleofection, the cells were immediately mixed with 500 mL of prewarmed F-12 Hams cell culture medium and transferred into 6-well plates containing 1.5 mL F-12 Hams medium per well. Cells were incubated at 37uC for 24 h before treatment. After 72 h of treatment, the cells were analyzed using a Beckman Dickinson LSR II flow cytometer.
Mice treatment by TMI-1
MMTV-ERRB2/neu mice were treated intraperitoneally with TMI-1 (100 mg/kg/d) or with vehicle (0.9% NaCl, 0.5% methylcellulose, 2% Tween 80) for a period of 30 days. Injections started with the detection of the tumor. Tumor volume was calculated using the formula V = 0.52 ( L6W 2 ). Tumor volumes were combined when mice developed multiple tumors. Mice were weighted daily. After completion of the analysis, autopsy of mice was done.
Measurement of apoptosis in mouse tumors
DNA fragmentation in apoptotic cells was analyzed by the TUNEL assay (ApopTag detection kit, (Millipore)) as recommended by the manufacturer. Briefly, 4 mM sections of paraffinembedded fixed tissue were deparaffined with successive histolemon and ethanol washes, then treated with 20 mg/mL proteinase K for 15 min at RT. Endogenous peroxidase were quenched with 3% hydrogen peroxide. Digoxigenin-dNTPs were enzymatically added to the free 39OH DNA termini by terminal deoxynucleotidyl transferase (TdT) and revealed by the peroxidase antidigoxigenin antibody. Coloration was performed using the diaminobenzidine mixed substrate (Dako). Counterstaining was done with a solution of 1% methyl green for 5 min at RT. After distilled water and N-butanol washes, specimens were mounted in Pertex medium (CellPath). Observations were done using the Leica DMD108 digital microimaging device (Leica Microsystems GmbH).
Drug combination analyses
Combination between TMI-1 and docetaxel, doxorubicin and lapatinib was analyzed by combining drugs at constant molar ratio. Concentration range for each drug was determined from effective dose (ED) 50 values calculated using nonlinear regression analysis. Cells were treated with serial dilutions of drug alone or in combination at constant molar ratio. Results were analyzed using the Chou and Talalay method that integrates ED50 and the shape of the dose-effect curve (Calcusyn software, Biosoft) [11] . The Combination Index (CI) was calculated to evaluate between additive (CI = 1) or synergism (CI,1) or antagonism (CI.1) resulting from drug combinations.
Statistical analysis
Data are presented as mean 6 s.e.m and were analysed using Mann-Whitney test or ANOVA, Bonferroni's Multiple Comparison test (Prism software). P,0.05 was considered statistically significant.
Results
A metalloproteinase inhibitor inhibits the growth of breast tumor cells
Targeting ADAM-17 metalloproteinase activity has been recently described as a new alternative to treat breast tumors through inhibition of particular EGFR ligands and ERBB2 shedding. We tested a series of new ADAM-17 inhibitor compounds (TMI-1, TMI-2, TMI-005) for their potential ability to block tumor cell growth. These compounds belong to the class of sulphonamide hydroxamate agents. TMI-1 and TMI-005 have a closely related structure ( Figure 1A ). They are dual inhibitor for ADAM-17 and some other metalloproteinases and share similar inhibition spectra towards these metalloproteinases. TMI-005 (Apratastat) has been used in clinics for the treatment of a chronic inflammatory disease [12] . Concerning TMI-2, it is selective for ADAM-17 [13] . Other compounds previously used to treat patients with cancer were also tested. These are marimastat, tanomastat, and batimastat, which are commercially available matrix metalloproteinase (MMP) inhibitors [14] . In addition, TAPI-1, a broad spectrum MMP/ADAM dual inhibitor currently used in vitro, was tested.
We used the breast tumor cell line SUM149 (derived from an inflammatory breast carcinoma of basal subtype) to test the cell growth inhibition by these drugs at concentrations ranging from 0 mM to 20 mM. TMI-1 induced a marked dose-dependent inhibition of the growth of SUM149 cells with an ED50 value of 1.5 mM. At the end of the experiment, relative fluorescent level was below the input level suggesting a cytotoxic effect of TMI-1 on these cells ( Figure 1B ). TMI-2 and TMI-005, showed limited effect on SUM149 growth with no measurable ED50 value. The other compounds had no effect.
We extended TMI-1 inhibition tests to a panel of breast tumor cell lines representative of the different molecular subtypes (basal, ERBB2 and luminal). As shown in Table 1 , TMI-1 inhibited 8 out of 9 tested tumor cell lines, with ED50 values comprised between 1.3 to 8.1 mM. These cells were faintly or not inhibited by TMI-2 or TMI-005 (data not shown). Interestingly, TMI-1 did not affect the viability of non tumoral and normal cells (n = 6). TMI-1 is thus a potent selective inhibitor for breast tumor cells of basal, ERBB2 and luminal molecular subtypes.
TMI-1 treatment induces caspase-dependent apoptosis in human breast tumor cells
To characterize the impact of TMI-1 on cell viability we measured the consequence of treatment on cell cycle progression and apoptosis. TMI-1 treatment for 48 h resulted in a dosedependent cell cycle arrest in the G0/G1 phase ( Figure 2A and Figure S1 ), and a dose-dependent annexin V staining, with 5 mM TMI-1 inducing annexin V staining in 40% of treated cells following 48 h treatment ( Figure 2B ). No annexin V positive cells were detected following treatment with TMI-2 and TMI-005 ( Figure 2B ). Annexin V positive cells were detected 12 h after TMI-1 treatment, inferring that TMI-1 induced apoptosis is rather an early event (data not shown). Measurement of executioner caspase-3/7 activity showed a dose dependent activation by TMI-1 but not by TMI-2 and TMI-005 ( Figure 2C ). Treatment of cells by the non-selective caspase inhibitor Z-VAD-FMK markedly reduced TMI-1-induced cell growth inhibition (30%) and apoptosis (100%) ( Figures 2D and 2E and Figure S2 , left column). The residual growth inhibition observed in the presence of Z-VAD-FMK could correspond to TMI-1 inhibitory effect on cell cycle. Treatment of non-tumoral mammary epithelial cells MCF-10A did not induce annexin V staining or caspase-3/7 activity ( Figures 2F and 2G) . Actually, caspase-3/7 activity was not induced at all in all the non-tumoral and normal cell lines we tested (Table 1) . In contrast, TMI-1 induced caspase-3/7 activity in all the sensitive breast tumor cell lines (Table 1) .
It is of note that TMI-1-induced cell cycle inhibition, caspase activation and annexin V staining (measured at 48 h) were observable at micromolar range concentration compatible with TMI-1 concentration affecting cell viability (measured at 120 h). Associated with Z-VAD inhibition, these data suggest that cell cycle inhibition and apoptosis induction are early biological events triggered by TMI-1 treatment and responsible for tumor cell growth inhibition.
TMI-1-induced apoptosis occurs through the extrinsic pathway
Apoptosis induced by anticancer drugs involves the intrinsic mitochondrial pathway and/or elements of the death receptor signaling pathway, the so-called extrinsic pathway of apoptosis [15] . We sought to determine the mechanism by which TMI-1 triggers apoptosis in SUM149 cells. As shown in Figure 3A , we found a dose-dependent activation of caspase-8 and caspase-9 upon TMI-1 treatment.
Processed caspase-8 is associated with activation of the extrinsic pathway. The implication of the extrinsic pathway in TMI-1-induced cell death was verified using the Z-IETD caspase-8 inhibitor which blocks apoptosis at 95% ( Figure 3B and Figure S2 , bottom right). Consistent with these results, transfection of a dominant-negative form of FADD (FAS-Associated protein with Death Domain) (FADD-DN) in TMI-1-treated SUM149 cells induced an 82% reduction of annexin V staining. As expected, a FADD-DN mutant (FADD-DNm), which in contrast to FADD-DN did not compete with endogenous FADD binding, did not significantly reduced annexin V staining ( Figure 3C ). Together, these results demonstrate that TMI-1 induces apoptosis through the activation of the extrinsic pathway. This seems to be a general mechanism of action as we found activation of the extrinsic pathway in two other sensitive breast cell lines, BT20 and SK-BR-3 ( Figure S3 ). However, this does not exclude a participation of the intrinsic pathway.
We tested the implication of the intrinsic pathway by measuring the enhancement of reactive oxygen species (ROS) generation. As shown in Figure 3D , we found a slight but reproducible dosedependent increase of ROS generation in SUM149 cells. However, the uncoupler of oxidative phosphorylation CCCP clearly generated more ROS than TMI-1 ( Figure 3D ). We found no decrease in mitochondrial membrane potential using the diOC6 cationic lipophilic dye (data not shown). From these two results we can conclude that TMI-1 acts mainly throughout the extrinsic pathway.
TMI-1 alone prevents MMTV-ErbB2/neu tumor evolution TMI-1 has been successfully used in mouse models of arthritis and kidney diseases to target and inhibit ADAM-17-mediated TNFa (Tumor Necrosis Factora) and TGFa (Transforming Growth Factora) release, respectively. TMI-1 pharmacokinetics in Balb/CJ mice indicated a C max value of 3 mM for one dose of 50 mg/kg. This value is compatible with the ED50 we found in vitro (Table 1 ). This inhibitor is well tolerated in mice and rats at concentrations up to 200 mg/kg/day and 600 mg/kg/day, respectively. To test TMI-1 efficiency in a preclinical model of breast cancer, we focused on ERBB2-overexpressing breast cancer. Indeed, we found that ERBB2-overexpressing cell lines are sensitive to TMI-1 as was a cell line derived from MMTVErbB2/neu tumor overexpressing activated ErbB2/neu (TgNeu27) ( Figure 4A and Table 1 ). To this end the transgenic MMTV-ErbB2/neu mouse was selected. This mouse model is a faithful model of spontaneous mammary gland carcinogenesis due to overexpression of the ErbB2/neu proto-oncogene and has been previously used to test the efficacy of drug therapies for breast cancer [16, 17, 18] . Because MMTV-ErbB2/neu mice progressively developed multifocal mammary tumors this model is also interesting to test tumor occurrence. Mice were treated at tumor onset for 30 days. Four mice (designated m0 to m3) were administered with TMI-1 at a dose of 100 mg/kg and three (m4 to m6) with vehicle alone. No adverse effects were noted during the treatment with the inhibitor as seen by mice behavior, body weight measurements and autopsy (data not shown). Daily administration of TMI-1 led to an 82% inhibition of mammary tumor growth compared to controls ( Figure 4B ). Interestingly, TMI-1 treatment prevented the occurrence of additional tumors ( Figure 4C ). Mice treated with the vehicle developed two or three tumors during the same period of observation, while no new tumors were detected in mice treated with TMI-1 ( Figure 4C ). In one case (mouse m2) we found a regression of the primary tumor upon TMI-1 treatment ( Figure 4C ). Apoptosis in tumors was measured in TMI-1 treated Figure 4D ). Together, these results showed that TMI-1 is efficient in ErbB2/neu mice model by inducing tumor apoptosis. Treatment of mice with TMI-1 slowed down mammary gland tumor growth and prevented tumor occurrence without detectable adverse effect.
TMI-1 combines efficiently with and doxorubicin, docetaxel or lapatinib
Anthracyclines and taxanes are the standard of care for breast cancer treatment. They can be associated with each other or with other drugs, depending on histoclinical classification. The dual EGFR/ERBB2 tyrosine kinase inhibitor lapatinib is currently used as an adjuvant therapy in breast cancer. We sought to evaluate the interest of TMI-1 treatment in combination therapy with doxorubicin, docetaxel or lapatinib. The optimal molar ratio for each drug combination on the SUM149 cell line was determined based on their respective ED50 values. Cells were treated with serial dilutions of each drug either individually or in combination in a fixed ratio. The anti-tumoral action of TMI-1 was potentiated by docetaxel, doxorubicin and lapatinib ( Figure 5A , B, C (left)), respectively.
The calculation of a combination index (CI) allows a quantitative definition for additive effect (CI = 1), synergism (CI,1), and antagonism (CI.1) in drug combinations. As shown in Figure 5A , B, C (right), synergism (CI,1) was observed for the three drug combinations and for the different ratio of concentrations. In some cases, CI values were low (,0.5) suggesting that, at these concentrations, the synergistic effect was marked. These results identify TMI-1 as a potent synergistic drug for breast cancer therapy. The data may indicate that mechanisms linked to TMI-1-induced cytotoxicity are different from the three other drugs tested.
TMI-1 inhibits tumorsphere formation and Aldefluorpositive cells
Cancer stem cells (CSCs) are thought to contribute to tumor initiation, maintenance, resistance to therapy, and metastasis progression [19, 20] . Treatment with drugs enrich in resistant CSCs [4] . In vitro, breast CSCs form tumorspheres and express high level of aldehyde dehydrogenase-1 (ALDH1), which can be detected by using a commercial assay (CSCs are ''Aldefluor'' positive) [21, 22] . The SUM149 cell line has CSCs that show these properties and have been extensively used as in vitro and in vivo CSC model [23] . To be efficient on a breast tumor or cell line a therapeutic drug should target the CSCs. We thus wanted to determine whether TMI-1 was active on CSCs.
To generate tumorspheres, SUM149 cells (pre-treated or not by TMI-1) were plated in serum-free medium and low adherence culture conditions. TMI-1 pre-treatment reduced significantly the formation of tumorspheres in primary and secondary assays ( Figures 6A and 6B ). This impact of TMI-1 on CSCs was confirmed by the Aldefluor test that showed a marked decrease in Aldefluor-positive cells upon TMI-1 treatment ( Figure 6C ). In the same conditions, TMI-005 only slightly affected the pool of CSCs, whereas doxorubicin increased it ( Figure 6D ). Together, these data show that TMI-1 affects the pool of CSCs in SUM149 cells.
TMI-1 cytotoxicity towards various tumor cell lines
Finally, to extend our results to several types of cancer, we tested the sensitivity of a total of 40 tumor cells from different origins. We integrated both ED50 value and the status of caspase-3/7 activity (+ or 2) ( Table 2 ). Based on ED50 and caspase-3/7 activity, TMI-1 was effective in 82% of the tested tumor cell lines. We defined that 44% of cell lines were highly sensitive to TMI-1 with ED50 values ranging from 0.6 mM to 2.5 mM. As seen previously for breast tumor cell lines (Table 1) , caspase-3/7 were found active in all but one TMI-1 sensitive cell lines. The DU145 prostate cell line was the only cell line sensitive that showed absence of caspase-3/7 activity. Activation of caspase-3/7 by TMI-1 was found to strongly correlate with tumor cell growth inhibition. Reciprocally, no caspase-3/7 activity was detected in normal cells, which were all resistant to TMI-1 treatment.
Thus, TMI-1 is a potent and selective inhibitor of tumor cell growth from different origins. No correlation with a specific type of tumor can be assessed from this analysis.
Discussion
We present here a metalloproteinase inhibitor with unexpected properties in the field of anti-tumor therapy. TMI-1 works at submicromolar range concentration to induce cell cycle inhibition and tumor cell death via caspase-dependent apoptosis. We found that 82% of tumor cell lines tested are sensitive to TMI-1 compared to 0% for normal cells.
TMI-1 belongs to the class of thiomorpholine hydroxamate inhibitors. It was initially designed to treat patients with chronic inflammatory diseases through the inhibition of ADAM-17 metalloproteinase involved in the shedding of TNFa [10] . ADAM-17 is a cell surface protein that sheds multiple transmembrane proteins, especially EGFR ligands and ERBB2 [24] . This cell line is highly sensitive to TMI-1 as seen by cell growth inhibition and caspase-3/7 activation (bottom)B: MMTV-ErbB2/neu transgenic mice were injected daily IP with TMI-1 (n = 4) or with the vehicle of TMI-1 (n = 3). C: Tumor-cumulated volumes were assessed by adding the volumes of the primary tumors to the volumes of the other tumors developed in the same mouse. The number of tumors developed in the same mouse within the ADAM-17 has thus been presented as a potent target in breast and lung cancers [25] . The ADAM-17 inhibitor INCB7839 has been shown to partially inhibit tumor cell growth at concentrations over 10 mM and synergized with targeted and cytotoxic drugs [26, 27] .
Interestingly, this inhibitor is currently undergoing early clinical trials in association with Herceptin in ERBB2-positive advanced breast cancer patients.
observation time (30 days) is indicated on the graph. D: TUNEL assay on tumors derived from MMTV-ErbB2/neu mice treated with vehicle (left) or TMI-1 (right) for 30 days (magnification: X100 (top), X400 (bottom)). doi:10.1371/journal.pone.0043409.g004 Figure 5 . Association of TMI-1 with therapeutic drugs in vitro. SUM149 cells were incubated for 5 days with serial dilutions of TMI-1 (0.58-9.32 mM) and Docetaxel (14.87610
26
-238610 26 mM) (A), doxorubicin (0.088-1.41 mM) (B), and lapatinib (0.17-2.72 mM) (C) individually or in combination at constant molar ratio. Determination between antagonism, additivity or synergism was evaluated using median-effect principle proposed by the Chou-Talalay method [11] . The CalcuSyn software was used to determine the CI. doi:10.1371/journal.pone.0043409.g005
Our data obtained with TMI-1 and its analogs TMI-005 and TMI-2 suggest that TMI-1 does not act through a mechanism strictly related to ADAM-17 inhibition. Indeed, we have established that these three inhibitors block the shedding of ADAM-17 targets such as TNFa, TGFa and amphiregulin (AREG) with the same efficacy (data not shown) whereas TMI-2 and TMI-005 only partially inhibit tumor cell growth and do not induce apoptosis. We also found that silencing expression of ADAM-17 results only in a moderate inhibition of cell growth, comparable to that observed with TMI-2 and TMI-005 (data not shown). We suggest from these data that apoptosis triggering by TMI-1 is not ADAM-17 dependent. This class of inhibitors acts by blocking the enzymatic catalytic Zn-binding site through their hydroxamate moiety. Interestingly, substitution of the hydroxamate moiety by a methyl group (TMI-1-O-CH3) ( Figure S4A ) profoundly altered the cytotoxic properties of TMI-1 ( Figure S4B ). This suggests that the thiomorpholine hydroxamate moiety could be implicated in TMI-1-induced apoptosis, through possible Of major interest is the fact that TMI-1 and TMI-005 have been found well tolerated in mice (up to 200 mg/kg/day/po) and rats (up to 600 mg/kg/day/po) [13, 28] . TMI-005 has been given to healthy volunteers up to 350 mg/po twice daily without any side effects [28] . The reason of this selectivity towards tumor cells is unclear. Recently, Moulick et al. described a small inhibitor that specifically targets tumor cells by blocking HSP90 only when engaged in cancer-specific but not in normal signaling networks [29] . Thus, there is increasing evidence that inhibitors may inhibit their target(s) according to the biological context. Tumor selectivity has been also described for HDAC (Histone deacetylase) inhibitor (HDACi) through TRAIL induction and triggering of the extrinsic apoptotic pathway [30] . HDACi belongs to a class of hydroxamate inhibitors that induce p21-dependent G1 cell cycle arrest. We found that TMI-1 did not induce p21, and did not act like an HDACi (data not shown). However, we have shown here that blocking the extrinsic pathway (FADD or caspase-8) led to apoptosis inhibition. This indicates that the apoptotic extrinsic pathway is activated upon TMI-1 treatment and that this pathway is necessary for triggering apoptosis.
Interestingly, TMI-1 inhibited 7 out of 9 breast tumor cell lines (ED50#2.5 mM) irrespectively of their molecular subtypes. It is of note that all the ERRB2-overexpressing cell lines were sensitive: breast (SK-BR-3, SUM190) and ovarian cell lines (TOV-112D, see Table 2 ), the murine TgNeu27 ''primary'' cell line derived from a MMTV-ErbB2/neu tumor and the L226 ''primary'' cell line derived from a patient with inflammatory breast carcinoma. The L226 ''primary'' cell line overexpressed ERBB2 (Herceptest 3+) and recapitulated genomic, transcriptomic and phenotypic characteristics of the patient tumor (Mezil et al. in preparation). Interestingly, SUM190 and L226 were resistant to Herceptin in vitro ( [31] and data not shown) meaning that TMI-1 may be an interesting alternative to treat the 70% of ERBB2 3+ patient that do not respond to Herceptin. Finally, TMI-1 slowed down tumor development and prevented the occurrence of new MMTVErbB2/neu mouse mammary tumors by inducing strong apoptosis. We noted tumor progression after completion of the treatment, strengthening the marked anti-tumoral in vivo effect of the drug used alone (data not shown). Together, these results suggest that patients with ERBB2-overexpressing tumors are eligible for TMI-1.
The inhibition of tumor occurrence observed in the mouse model is in accordance with the marked anti-CSCs effect of TMI-1. TMI-1 belongs to the (short) list of agents capable of targeting CSCs [20, 32] . Actually, some of these agents have been designed, like TMI-1, for the treatment of non-cancerous pathologies before drug repositioning towards cancer therapy (c-secretase inhibitor (GSI) for Alzheimer's disease, metformin for diabetes type II, repertaxin in inflammation diseases) (Table S1 ). In the case of metformin, molecular target(s) is (are) not identified and the mechanism of action is not fully understood [33] . Unfortunately, metformin affects the growth of non-transformed cells. Several ongoing randomized clinical trials that incorporate GSI and metformin as an adjuvant to chemotherapy are in progress.
Conclusions
TMI-1 is a promising drug for the treatment of breast cancer and probably other neoplasms. TMI-1 is selective towards tumor cells and presents reduced toxicity in vivo. TMI-1 targets CSCs and differentiated tumor cells and is synergistic with chemo-and targeted-therapy agents.
TMI-1 could be used in different therapeutic protocols. For example, it could be administered in the adjuvant setting after removal of the primary tumor, to prevent tumor occurrence.
This work identifies a new class of chemical compound in the field of cancer therapeutics and raises the exciting possibility to find, define and refine new therapeutic target(s) and new chemical analogues. 
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